GSK receives FDA approval for hepatitis B therapy that expands functional cure rates

GSK announced that the U.S. Food and Drug Administration has granted approval for its hepatitis B drug.

The agency said the treatment can achieve functional cures in a larger proportion of patients compared with existing therapies.

Data supporting the approval showed improved viral suppression and liver health outcomes, positioning the drug as a new option for chronic hepatitis B management.

The approval adds to GSK's infectious‑disease portfolio and could shift market dynamics for hepatitis B treatments.